Alcoholic and non-alcoholic steatohepatitis: Who is affected and what can we do for them?;Esteatohepatitis alcohólica y no alcohólica: ¿quiénes son los pacientes y qué podemos hacer por ellos?

Gastroenterologia y Hepatologia

Volumn 36, Issue 9, 2013, Pages 587-596

  Gallego Durán, Rocío ^a   Ampuero, Javier ^a   Funuyet, Jorge ^a   Romero Gómez, Manuel ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

Author keywords

Alcoholic steatohepatitis; Non alcoholic steatohepatitis; Noninvasive diagnosis; Pathogenic mechanisms of steatohepatitis; Therapeutic management

Indexed keywords

ALCOHOL; CYTOCHROME P450 2E1; INSULIN; TRANSFERRIN;

ALCOHOL CONSUMPTION; ALCOHOLIC FATTY LIVER; ANTHROPOMETRIC PARAMETERS; ARTICLE; BIOCHEMICAL COMPOSITION; DIET; EXERCISE; HUMAN; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPIDOMICS; LIVER BIOPSY; LIVER FIBROSIS; MICROFLORA; NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; QUESTIONNAIRE;

ALCOHOLIC STEATOHEPATITIS; DIAGNÓSTICO NO INVASIVO; ESTEATOHEPATITIS ALCOHÓLICA; ESTEATOHEPATITIS NO ALCOHÓLICA; MANEJO TERAPÉUTICO; NON-ALCOHOLIC STEATOHEPATITIS; NONINVASIVE DIAGNOSIS; PATHOGENIC MECHANISMS OF STEATOHEPATITIS; THERAPEUTIC MANAGEMENT; VÍAS PATOGÉNICAS DE ESTEATOHEPATITIS;

ALCOHOLISM; ANTIOXIDANTS; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; DIET, FAT-RESTRICTED; DISEASE SUSCEPTIBILITY; EXERCISE; FATTY LIVER; FATTY LIVER, ALCOHOLIC; HEPATITIS; HEPATOCYTES; HUMANS; OBESITY; PARENTERAL NUTRITION, TOTAL; QUESTIONNAIRES; TRIGLYCERIDES;

EID: 84887554859     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1016/j.gastrohep.2013.06.005     Document Type: Article

References (76)

1. Spelliotes E.K., Yerges-Armstrong L.M., Wu J., Hernaez R., Kim L.J., Palmer C.D., et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLos Genet 2011, 7:1001324.
2. Cohen J.C., Horton J.D., Hobbs H. Human fatty liver disease: Old questions and new insights. Science 2011, 332:1519-1523.
3. Adams L.A., Lymp J.F., St Sauver J., Sanderson S.O., Lindor K.O., Feldstein A., et al. The natural history of nonalcoholic fatty liver disease: A population-based cohort study. Gastroenterology 2005, 129:113-121.
4. Chalasani N., Younossi Z., Lavine J.E., Diehl A.M., Brunt E.M., Cusi K., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases. American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012, 2005:2023.
5. Rubio G. Validación de la prueba para la identificación de trastornos por el uso de alcohol (AUDIT) en atención primaria. Rev Clin Esp 1998, 198:11-14.
6. Bohn M.J., Babor T.F., Kranzler H.R. The Alcohol Use Disorders Identification Test (AUDIT): Validation of a screening instrument for use in medical settings. J Stud Alcohol 1995, 56:423-432.
7. Saiz P.A., Garcia-Portilla M.P., Bousoño M., Bobes J. Marcadores biológicos de la conducta alcohólica. Psiquiatr Biol 1998, 5(Supl 1):37.
8. Hock B., Schwarz M., Domke I., Grunert V.P., Wuertemberger M., Schiemann U., et al. Validity of carbohydrate-deficient transferrin (%CDT), gamma-glutamyltransferase (gamma-GT) and mean corpuscular erythrocyte volume (MCV) as biomarkers for chronic alcohol abuse: a study in patients with alcohol dependence and liver disorders of non-alcoholic and alcoholic origin. Addiction 2005, 100:1477-1486.
9. Guía de Referencia Rápida para abordar el Consumo de Alcohol 2005, Grupo de Educación Sanitaria y Promoción de la Salud del PAPPS, Sociedad Española de Medicina de Familia y Comunitaria, Madrid.
10. Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
11. Valls C., Iannacconne R., Alba E., Murakami T., Hori M., Passariello R., et al. Fat in the liver, diagnosis and characterization. Eur Radiol 2006, 16:2292-2308.
12. Nagai S., Fujimoto Y., Kamei H., Nakamura T., Kiuchi T. Mild hepatic macrovesicular steatosis may be a risk factor for hyperbilirubinaemia in living liver donors following right hepatectomy. Br J Surg 2009, 96:437-444.
13. Barr J., Caballería J., Martínez-Arranz I., Domínguez-Díez A., Alonso C., Muntané J., et al. Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression. J Proteome Res 2012, 11:2521-2532.
14. Feldstein A.E., Wieckowska A., Lopez A.R., Liu Y.C., Zein N.N., McCullogh A.J. Cytokeratin-18 fragment levels as noinvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009, 50:1072-1078.
15. Milner K.L., van der Poorten D., Xu A., Bugianesi E., Kench J.G., Lam K.S., et al. Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology 2009, 49:1926-1934.
16. Li H., Fang Q., Gao F., Fan J., Zhou J., Wang X., et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol 2010, 53:934-940.
17. Shen J., Lik-Yuen Chan H., Lai-Hung Wong G., Cheung-Lung Choi P., Wing-Hung Chan A., Chan H.Y., et al. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. J Hepatol 2012, 56:1363-1370.
18. Monteanu M., Ratziu V., Morra R., Messous D., Imbert-Bismut F., Poynard T. Noninvasive biomarkers for the screening of fibrosis. steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMaxTM Experience. J Gastrointestin Liver Dis 2008, 17:187-191.
19. Wong V.W., Vergniol J., Wong G.L., Foucher J., Chan H.L., Le Bail B., et al. Diagnosis of fibrosis and cirrhosis using liver stifness measurement in nonalcoholic fatty liver disease. Hepatology 2010, 51:454-462.
20. Schwenzer N.F., Springer F., Schraml C., Stefan N., Machann J., Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol 2009, 51:433-445.
21. Strauss S., Gavish E., Gottlieb P., Katsnelson L. Interobserver and intraobserver variability in the sonographic assessment of fatty liver. Am J Roetgenol 2007, 189:320-323.
22. Lee S.S., Park S.H., Kim H.J., Kim S.Y., Kim M.-Y., Kim D.Y., et al. Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations. J Hepatol 2010, 52:579-585.
23. Gallego-Durán R., Cerro-Salido P., Gómez-González E., Pareja M.J., Aznar R., Macho S., et al. Determination of fibrosis stage and steatohepatitis in patients with NAFLD by optical analysis of magnetic resonance images combined with artificial neural networks (FIBROMRi and NAHMRi). J Hepatol 2013, 58 Supl. 1:S1-S24.
24. Kanuri G., Loescher M., Stahl C., Bischoff S.C., Bergheim I. Effect of moderate alcohol consumption on the development of non-alcoholic fatty liver disease (NAFLD) in ob/ob mice. Hepatology 2012, 56:874.
25. Moriya A., Iwasaki Y., Ohguchi S., Kayashima E., Mitsumune T., Taniguchi H., et al. Alcohol consumption appears to protect against non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2011, 33:378-388.
26. Nagata K., Suzuki H., Sakaguchi S. Common pathogenic mechanism in development progression of liver injurycaused bynon-alcoholic or alcoholic steatohepatitis. J Toxicol Sci 2007, 32:453-468.
27. Forgione A., Miele L., Cefalo C., Gasbarrini G., Grieco A. Alcoholic and nonalcoholic forms of fatty liver disease. Minerva Gastroenterol Dietol 2007, 53:83-100.
28. Völzke H. Multicausality in fatty liver disease: is there a rationale to distinguish between alcoholic and non-alcoholic origin?. World J Gastroenterol 2012, 18:3492-3501.
29. Wheeler M.D. Endotoxin and Kupffer cell activation in alcoholic liver disease. Alcohol Res Health 2003, 27:300-306.
30. Iimuro Y., Bradford B.U., Yamashina S., Rusyn I., Nakagami M., Enomoto N., et al. The glutathione precursor L-2-oxothiazolidine-4-carboxylic acid protects against liver injury due to chronic enteral ethanol exposure in the rat. Hepatology 2000, 31:391-398.
31. Lu Y., Cederbaum A.I. CYP2E1 and oxidative liver injury by alcohol. Free Radic Biol Med 2008, 44:723-738.
32. Day C.P., James O.F. Steatohepatitis: A tale of two «hits»?. Gastroenterology 1998, 114:842-845.
33. Aubert J., Begriche K., Knockaert L., Robin M.A., Fromenty B. Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: Mechanisms and pathophysiological role. Clin Res Hepatol Gastroenterol 2011, 35:630-637.
34. Osabe M., Sugatani J., Fukuyama T., Ikushiro S., Ikari A., Miwa M. Expression of hepatic UDP-glucuronosyltransferase 1A1 and 1A6 correlated with increased expression of the nuclear constitutive androstane receptor and peroxisome proliferator-activated receptor alpha in male rats fed a high-fat and highsucrose diet. Drug Metab Dispos 2008, 36:294-302.
35. Thuy S., Ladurner R., Volynets V., Wagner S., Strahl S., Königsrainer A., et al. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr 2008, 138:1452-1455.
36. Baffy G. Kupffer cells in non-alcoholic fatty liver disease: the emerging view. J Hepatol 2009, 51:212-223.
37. Bonini J.A., Colca J.R., Dailey C., White M., Hofmann C. Compensatory alterations for insulin signal transduction and glucose transport in insulin-resistant diabetes. Am J Physiol 1995, 269:759-765.
38. Kulik G., Klippel A., Weber M.J. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol 1997, 17:1595-1606.
39. de la Monte S., Derdak Z., Wands J.R. Alcohol, insulin resistance and the liver-brain axis. J Gastroenterol Hepatol 2012, 27(Suppl 2):33-41.
40. De la Monte S.M., Yeon J.E., Tong M., Longato L., Chaudhry R., Pang M.Y., et al. Insulin resistance in experimental alcohol-induced liver disease. J Gastroenterol Hepatol 2008, 23:477-486.
41. Tamura S., Shimomura I. Contribution of adipose tissue and de novo lipogenesis to non alcoholic fatty liver disease. J Clin Invest 2005, 115:1139-1142.
42. Frederico M.J., Vitto M.F., Cesconetto P.A., Engelmann J., De Souza D.R., Luz G., et al. Short-term inhibition of SREBP-1c expression reverses diet-induced non-alcoholic fatty liver disease in mice. Scand J Gastroenterol 2011, 46:1381-1388.
43. Cohen J., Horton J., Hobbs H. Human fatty liver disease: old questions and new insights. Science 2011, 232.
44. Dubuquoy C., Robichon C., Lasnier F., Langlois C., Dugail I., Foufelle F., et al. Distinct regulation of adiponutrin/PNPLA3 gene expression by the transcription factors ChREBP and SREBP1c in mouse and human hepatocytes. J Hepatol 2011, 55:145-153.
45. Romeo S., Kozlitina J., Xing C., Pertsemlidis A., Cox D., Pennacchio L.A., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008, 40:1461-1465.
46. Stickel F., Buch S., Lau K., Meyer zu Schwabedissen H., Berg T., Ridinger M., et al. Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians. Hepatology 2011, 53:86-95.
47. Trépo E., Gustot T., Degré D., Lemmers A., Verset L., Demetter P., et al. Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease. J Hepatol 2011, 55:906-912.
48. Abu-Shanab A., Quigley E.M. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010, 7:691-701.
49. Eckburg P.B., Bik E.M., Bernstein C.N., Purdom E., Dethlefsen L., Sargent M., et al. Diversity of the human intestinal microbial flora. Science 2005, 308:1635-1638.
50. Arumugam M., Raes J., Pelletier E., le Paslier D., Yamada T., Mende D.R., et al. Enterotypes of the human gut microbiome. Nature 2011, 473:174-180.
51. Zhu L., Baker S.S., Gill C., Liu W., Alkhouri R., Baker R.D., et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH. Hepatology. 2013, 57:601-609.
52. Loria P., Adinolfi L.E., Bellentani S., Bugianesi E., Grieco A., Fargion S., et al. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Commitee. Dig Liver Dis 2010, 42:272-282.
53. Thoma C., Day C.P., Trenell M.I. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review. J Hepatology 2012, 56:255-266.
54. Zelber-Sagi S., Nitzan-Kaluski D., Goldsmith R., Webb M., Blendis L., Halpern Z., et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatol 2007, 47:711-717.
55. Bae J.C., Suh S., Park S.E., Rhee E.J., Park C.Y., Oh K.W., et al. Regular exercise is associated with a reduction in the risk of NAFLD and decreased liver enzymes in individuals with NAFLD independent of obesity in Korean adults. PLoS One 2012, 7:e46819. 10.1371/journal.pone.0046819.
56. Promrat K., Kleiner D.E., Niemeier H.M., Jackvony E., Kearns M., Wands J.R., et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010, 51:121-129.
57. Pessione F., Ramond M.J., Peters L., Pham B.N., Batel P., Rueff B., et al. Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence. Liver Int 2003, 23:45-53.
58. Zillikens M.C., van den Berg J.W., Wattimena J.L., Rietveld T., Swart G.R. Nocturnal oral glucose supplementation. The effects on protein metabolism in cirrhotic patients and in healthy controls. J Hepatol 1993, 17:377-383.
59. Sreenivasa Baba C., Alexander G., Kalyani B., Pandey R., Rastogi S., Pandey A., et al. Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis. J Gastroenterol Hepatol 2006, 21:191-198.
60. Fromrat K., Kleiner D.E., Niemeier H.M., Jackvony E., Kearns M., Wands J.R., et al. Randomized controlled clinical trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010, 51:121-129.
61. Lazo M., Solga S.F., Horska A., Bonekamp S., Diehl A.M., Brancati F.L., et al. Effect on a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type-2 diabetes. Diabetes Care 2010, 33:2156-2163.
62. Marchesini G., Brizi M., Bianchi G., Tomassetti S., Zoli M., Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 2001, 358:893-894.
63. Nair S., Diehl A.M., Wiseman M., Farr G.H., Perrillo R.P. Metformin in the treatment of non-alcoholic steatohepatitis: A pilot open label trial. Aliment Pharmacol Ther 2004, 20:23-28.
64. Haukeland J.W., Konopski Z., Eggesbø H.B., von Volkmann H.L., Raschpichler G., Bjøro K., et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol 2009, 44:853-860.
65. Vernon G., Baranova A., Younossi Z.M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and nonalcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011, 34:274-285.
66. Chalasani N., Younossi Z., Lavine J.E., Diehl A.M., Brunt E.M., Cusi K., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases. American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012, 55:2005-2023.
67. Ramirez T., Tong M., Chen W.C., Nguyen Q.G., Wands J.R., de la Monte S.M. Chronic alcohol-induced hepatic insulin resistance and ER stress ameliorated by PPAR-δ agonist treatment. J Gastroenterol Hepatol 2012, 10.1111/j.1440-1746.
68. Neuschwander-Tetri B.A., Brunt E.M., Wehmeier K.R., Oliver D., Bacon B.R. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003, 38:1008-1017.
69. Belfort R., Harrison S.A., Brown K., Darland C., Finch J., Hardies J., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006, 355:2297-2307.
70. Aithal G.P., Thomas J.A., Kaye P.V., Lawson A., Ryder S.D., Spendlove I., et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008, 135:1176-1184.
71. Zingg J.M. Vitamin E: An overview of major research directions. Mol Aspects Med 2007, 28:400-422.
72. French S.W., Benson N.C., Sun P.S. Centrilobular liver necrosis induced by hypoxia in chronic ethanol-fed rats. Hepatology 1984, 4:912-917.
73. de la Maza M.P., Petermann M., Bunout D., Hirsch S. Effects of long-term vitamin E supplementation in alcoholic cirrhotics. J Am Coll Nutr 1995, 14:192-196.
74. Sanyal A.J., Chalasani N., Kowdley K.V., McCullough A., Diehl A.M., Bass N.M., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010, 362:1675-1685.
75. Bjelakovic G., Nikolova D., Gluud L.L., Simonetti R.G., Gluud C. Mortality in randomized trials of antioxidant supplements of primary and secondary prevention: Systematic review and meta-analysis. JAMA 2007, 297:842-857.
76. Pamuk G.E., Sonsuz A. N-acetylcysteine in the treatment of non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2003, 18:1220-1221.